
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
There's been good news lately for sufferers of eczema, the itchy andoften painful inflammatory skin disease that affects more than 15 millionAmericans. Until recently, only steroids could normalize skin. But a nonsteroidalprescription drug called Protopic is now available.